Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial
CONCLUSIONS: MAGNITUDE, enrolling the largest BRCA1/2 cohort in first-line mCRPC to date, demonstrated improved rPFS and other clinically relevant outcomes with niraparib plus AAP in patients with BRCA1/2-altered mCRPC, emphasizing the importance of identifying this molecular subset of patients.PMID:37399894 | DOI:10.1016/j.annonc.2023.06.009 (Source: Ann Oncol)
Source: Ann Oncol - July 3, 2023 Category: Cancer & Oncology Authors: K N Chi S Sandhu M R Smith G Attard M Saad D Olmos E Castro G Roubaud A J Pereira de Santana Gomes E J Small D E Rathkopf H Gurney W Jung G E Mason S Dibaj D Wu B Diorio K Urtishak A Del Corral P Francis W Kim E Efstathiou Source Type: research
Saracatinib synergizes with enzalutamide to downregulate AR activity in CRPC
Prostate cancer (PCa) remains the most diagnosed non-skin cancer amongst the American male population. Treatment for localized prostate cancer consists of androgen deprivation therapies (ADTs), which typically inhibit androgen production and the androgen receptor (AR). Though initially effective, a subset of patients will develop resistance to ADTs and the tumors will transition to castration-resistant prostate cancer (CRPC). Second generation hormonal therapies such as abiraterone acetate and enzalutamide are typically given to men with CRPC. However, these treatments are not curative and typically prolong survival only b...
Source: Frontiers in Oncology - June 30, 2023 Category: Cancer & Oncology Source Type: research
Adherence to hormone therapy in patients with mCRPC: psychometric validation of the A-HT questionnaire
Clin Ter. 2023 Jul-Aug;174(4):345-352. doi: 10.7417/CT.2023.2449.ABSTRACTThe incidence rate of prostate cancer (PCa) in many Western countries is high, contributing greatly to the cancer disease bur-den. In most cases, patients progress to metastatic disease defined as castration-resistant prostate cancer after androgen deprivation (mCRPC) following primary treatment where the majority of patients receive first-line new-generation oral hormonal therapies (HT) such as Abiraterone Acetate (AA) and Enzalutamide (ENZ). Despite the importance of correct intake of these drugs, adherence in patients with mCRPC is still poorly inv...
Source: Clinical Prostate Cancer - June 28, 2023 Category: Cancer & Oncology Authors: L Iacorossi F Gambalunga M Piredda I Terrenato C Marzo R Latina I Notarnicola T Bolgeo M G De Marinis P Carlini Source Type: research
Adherence to hormone therapy in patients with mCRPC: psychometric validation of the A-HT questionnaire
Clin Ter. 2023 Jul-Aug;174(4):345-352. doi: 10.7417/CT.2023.2449.ABSTRACTThe incidence rate of prostate cancer (PCa) in many Western countries is high, contributing greatly to the cancer disease bur-den. In most cases, patients progress to metastatic disease defined as castration-resistant prostate cancer after androgen deprivation (mCRPC) following primary treatment where the majority of patients receive first-line new-generation oral hormonal therapies (HT) such as Abiraterone Acetate (AA) and Enzalutamide (ENZ). Despite the importance of correct intake of these drugs, adherence in patients with mCRPC is still poorly inv...
Source: Clinical Breast Cancer - June 28, 2023 Category: Cancer & Oncology Authors: L Iacorossi F Gambalunga M Piredda I Terrenato C Marzo R Latina I Notarnicola T Bolgeo M G De Marinis P Carlini Source Type: research
Adherence to hormone therapy in patients with mCRPC: psychometric validation of the A-HT questionnaire
Clin Ter. 2023 Jul-Aug;174(4):345-352. doi: 10.7417/CT.2023.2449.ABSTRACTThe incidence rate of prostate cancer (PCa) in many Western countries is high, contributing greatly to the cancer disease bur-den. In most cases, patients progress to metastatic disease defined as castration-resistant prostate cancer after androgen deprivation (mCRPC) following primary treatment where the majority of patients receive first-line new-generation oral hormonal therapies (HT) such as Abiraterone Acetate (AA) and Enzalutamide (ENZ). Despite the importance of correct intake of these drugs, adherence in patients with mCRPC is still poorly inv...
Source: Clinical Genitourinary Cancer - June 28, 2023 Category: Cancer & Oncology Authors: L Iacorossi F Gambalunga M Piredda I Terrenato C Marzo R Latina I Notarnicola T Bolgeo M G De Marinis P Carlini Source Type: research
Adherence to hormone therapy in patients with mCRPC: psychometric validation of the A-HT questionnaire
Clin Ter. 2023 Jul-Aug;174(4):345-352. doi: 10.7417/CT.2023.2449.ABSTRACTThe incidence rate of prostate cancer (PCa) in many Western countries is high, contributing greatly to the cancer disease bur-den. In most cases, patients progress to metastatic disease defined as castration-resistant prostate cancer after androgen deprivation (mCRPC) following primary treatment where the majority of patients receive first-line new-generation oral hormonal therapies (HT) such as Abiraterone Acetate (AA) and Enzalutamide (ENZ). Despite the importance of correct intake of these drugs, adherence in patients with mCRPC is still poorly inv...
Source: Clinical Prostate Cancer - June 28, 2023 Category: Cancer & Oncology Authors: L Iacorossi F Gambalunga M Piredda I Terrenato C Marzo R Latina I Notarnicola T Bolgeo M G De Marinis P Carlini Source Type: research
Adherence to hormone therapy in patients with mCRPC: psychometric validation of the A-HT questionnaire
Clin Ter. 2023 Jul-Aug;174(4):345-352. doi: 10.7417/CT.2023.2449.ABSTRACTThe incidence rate of prostate cancer (PCa) in many Western countries is high, contributing greatly to the cancer disease bur-den. In most cases, patients progress to metastatic disease defined as castration-resistant prostate cancer after androgen deprivation (mCRPC) following primary treatment where the majority of patients receive first-line new-generation oral hormonal therapies (HT) such as Abiraterone Acetate (AA) and Enzalutamide (ENZ). Despite the importance of correct intake of these drugs, adherence in patients with mCRPC is still poorly inv...
Source: Clinical Breast Cancer - June 28, 2023 Category: Cancer & Oncology Authors: L Iacorossi F Gambalunga M Piredda I Terrenato C Marzo R Latina I Notarnicola T Bolgeo M G De Marinis P Carlini Source Type: research
Adherence to hormone therapy in patients with mCRPC: psychometric validation of the A-HT questionnaire
Clin Ter. 2023 Jul-Aug;174(4):345-352. doi: 10.7417/CT.2023.2449.ABSTRACTThe incidence rate of prostate cancer (PCa) in many Western countries is high, contributing greatly to the cancer disease bur-den. In most cases, patients progress to metastatic disease defined as castration-resistant prostate cancer after androgen deprivation (mCRPC) following primary treatment where the majority of patients receive first-line new-generation oral hormonal therapies (HT) such as Abiraterone Acetate (AA) and Enzalutamide (ENZ). Despite the importance of correct intake of these drugs, adherence in patients with mCRPC is still poorly inv...
Source: Clinical Genitourinary Cancer - June 28, 2023 Category: Cancer & Oncology Authors: L Iacorossi F Gambalunga M Piredda I Terrenato C Marzo R Latina I Notarnicola T Bolgeo M G De Marinis P Carlini Source Type: research
Genomic profiling of metastatic castration-resistant prostate cancer samples resistant to androgen-receptor pathway inhibitors
CONCLUSIONS: Low AR activity, activation of stemness programs, and Hedgehog pathway were associated with primary ARPIs' resistance, whereas most acquired resistance was associated with subclonal evolution, AR-related events, and neuroendocrine differentiation.PMID:37364000 | DOI:10.1158/1078-0432.CCR-22-3736 (Source: Cell Research)
Source: Cell Research - June 26, 2023 Category: Cytology Authors: Naoual Menssouri Loic Poiraudeau Carole Helissey Ludovic Bigot Jonathan Sabio Tony Ibrahim Cedric Pobel Claudio Nicotra Maud Ngo-Camus Ludovic Lacroix Etienne Rouleau Lambros Tselikas Anne Chauchereau F élix Blanc-Durand Alice Bernard-Tessier Anna Patrik Source Type: research
Genomic profiling of metastatic castration-resistant prostate cancer samples resistant to androgen-receptor pathway inhibitors
CONCLUSIONS: Low AR activity, activation of stemness programs, and Hedgehog pathway were associated with primary ARPIs' resistance, whereas most acquired resistance was associated with subclonal evolution, AR-related events, and neuroendocrine differentiation.PMID:37364000 | DOI:10.1158/1078-0432.CCR-22-3736 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - June 26, 2023 Category: Cancer & Oncology Authors: Naoual Menssouri Loic Poiraudeau Carole Helissey Ludovic Bigot Jonathan Sabio Tony Ibrahim Cedric Pobel Claudio Nicotra Maud Ngo-Camus Ludovic Lacroix Etienne Rouleau Lambros Tselikas Anne Chauchereau F élix Blanc-Durand Alice Bernard-Tessier Anna Patrik Source Type: research
Genomic profiling of metastatic castration-resistant prostate cancer samples resistant to androgen-receptor pathway inhibitors
CONCLUSIONS: Low AR activity, activation of stemness programs, and Hedgehog pathway were associated with primary ARPIs' resistance, whereas most acquired resistance was associated with subclonal evolution, AR-related events, and neuroendocrine differentiation.PMID:37364000 | DOI:10.1158/1078-0432.CCR-22-3736 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - June 26, 2023 Category: Cancer & Oncology Authors: Naoual Menssouri Loic Poiraudeau Carole Helissey Ludovic Bigot Jonathan Sabio Tony Ibrahim Cedric Pobel Claudio Nicotra Maud Ngo-Camus Ludovic Lacroix Etienne Rouleau Lambros Tselikas Anne Chauchereau F élix Blanc-Durand Alice Bernard-Tessier Anna Patrik Source Type: research
Genomic profiling of metastatic castration-resistant prostate cancer samples resistant to androgen-receptor pathway inhibitors
CONCLUSIONS: Low AR activity, activation of stemness programs, and Hedgehog pathway were associated with primary ARPIs' resistance, whereas most acquired resistance was associated with subclonal evolution, AR-related events, and neuroendocrine differentiation.PMID:37364000 | DOI:10.1158/1078-0432.CCR-22-3736 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - June 26, 2023 Category: Cancer & Oncology Authors: Naoual Menssouri Loic Poiraudeau Carole Helissey Ludovic Bigot Jonathan Sabio Tony Ibrahim Cedric Pobel Claudio Nicotra Maud Ngo-Camus Ludovic Lacroix Etienne Rouleau Lambros Tselikas Anne Chauchereau F élix Blanc-Durand Alice Bernard-Tessier Anna Patrik Source Type: research
Survival outcomes and prognostic factors for first-line abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer
To investigate the survival outcomes of metastatic castration-resistant prostate cancer (mCRPC) patients receiving first-line novel androgen receptor axis-targeted therapies (ARATs) and prognostic factors for ... (Source: BMC Cancer)
Source: BMC Cancer - June 20, 2023 Category: Cancer & Oncology Authors: Chi-Shin Tseng, Jui-Han Yang, Shi-Wei Huang, Yu-Jen Wang, Chung-Hsin Chen, Yeong-Shiau Pu, Jason Chia-Hsien Cheng and Chao-Yuan Huang Tags: Research Source Type: research
EPH27 Association between Prescribing Specialty and Treatment-Related Complications in Patients Using Novel Hormonal Agents for Metastatic Castration-Resistant Prostate Cancer: Population-Based Study
The objective was to assess the association between the incidence of NHA-related complications and prescribing specialty in mCRPC patients treated with NHAs. (Source: Value in Health)
Source: Value in Health - June 1, 2023 Category: International Medicine & Public Health Authors: J. Hu, A. Aprikian, A. Dragomir Source Type: research
